Bridging the Treatment Access Gap: Janus Kinase Inhibitors as First-line Advanced Therapy for Inflammatory Bowel Disease in Resource-variable Settings. (PubMed, Euroasian J Hepatogastroenterol) - Sep 27, 2026 - "With respect to onset kinetics, JAK inhibitors outpace every biologic class; upadacitinib produced symptomatic remission in 68% by week 2, contrasted with 15.7-22% for vedolizumab, ustekinumab, and tumor necrosis factor (TNF) antagonists...This review presents the first regionally anchored framework for deploying JAK inhibitors in clinical contexts where the operative decision is not between a JAK inhibitor and a biologic, but between a JAK inhibitor and the total absence of advanced therapy. For gastroenterologists practicing throughout the Euroasian region under conditions of restricted biologic availability, limited infusion capacity, and absent therapeutic drug monitoring (TDM), this review furnishes an evidence-grounded rationale for deploying JAK inhibitors as first-line advanced therapy, supported by efficacy data, safety evidence, and pragmatic considerations tailored to resource-variable healthcare systems."
Journal • Cardiovascular • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Herpes Zoster • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Oncology • Rheumatoid Arthritis • Rheumatology • Ulcerative Colitis • Varicella Zoster • Venous Thromboembolism
|
|
Benjamin Hewitt; Rowan Bandaranaike; Samuel Tarwater
|